
New abstracts show the oral PCSK9 inhibitor cut LDL-C by 57% to 63% across PREVENT risk groups, with reductions maintained in an extension study.
Supplements and Featured Publications
about 20 years ago
Quizabout 20 years ago
Asthma Treatment Guidelines and Use of Inhalers





